Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis’ Zykadia Sets New “Breakthrough” Speed Record For NME Review

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA grants accelerated approval to ceritinib following a four-month review. The ALK inhibitor is indicated for non-small cell lung cancer patients who have progressed on or are intolerant of Pfizer’s Xalkori.

You may also be interested in...



Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Genentech’s Alecensa Joins The ALK Inhibitor Market

Alectinib will launch within two weeks for second-line ALK-positive non-small lung cancer at the price of $12,500 per month.

Accelerated Approval Conversion Could Mean ‘Breakthrough’ Loss

Sponsors of ‘breakthrough therapy’-designated investigational oncology products may need to identify a niche subpopulation that remains underserved when a competing product with accelerated approval in the same indication completes confirmatory trials.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS077152

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel